✦ LIBER ✦

Farnesyltransferase inhibitors and myeloid malignancies: Phase I evidence of Zarnestra activity in high-risk leukemias

✍ Scribed by Jeffrey E Lancet; Joseph D Rosenblatt; Judith E Karp

Book ID: 117832592
Publisher: Elsevier Science
Year: 2002
Tongue: English
Weight: 123 KB
Volume: 39
Category: Article
ISSN: 1532-8686
DOI: 10.1053/shem.2002.35985

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase 1-2 study of a farnesyltransfera

A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome

✍ Elias Jabbour; Hagop Kantarjian; Farhad Ravandi; Guillermo Garcia-Manero; Zeev E 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 221 KB 👁 1 views

## Abstract ## BACKGROUND: The authors conducted a phase 1/2 study of tipifarnib in combination with idarubicin and cytarabine (IA) in 95 patients with previously untreated acute myeloid leukemia (AML) or high‐risk myelodysplastic syndrome. ## METHODS: Induction consisted of idarubicin 12 mg/m^2

A phase I/II study of oral etoposide and

A phase I/II study of oral etoposide and idarubicin in elderly patients with high-risk acute myeloid leukemia unable to undergo intensive chemotherapy

✍ Michael Fiegl; Thomas Büchner; Wolfgang Hiddemann; Jan Braess 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 84 KB